Next Generation Partners

Biotechnology in East Anglia


At Goodwin in Cambridge, ‘the team provides timely, pragmatic and and commercial advice‘ and clients note that the lawyers are ‘accessible, responsive and keen to understand our aims‘. David Mardle has broad expertise in life sciences, technology, M&A, and finance matters; commercial IP specialist Malcolm Bates, who has ‘broad and long experience' in R&D projects and collaboration agreements; and licensing and contracts expert Tim Worden are key to the practice. Worden acted as part of a multinational team to advise Biocon Biologics on its multibillion-dollar acquisition of the global biosimilars business of its partner Viatris Inc. Up-and-coming partner Elizabeth Rhodes handles corporate and venture capital matters for technology and life sciences companies.

Practice head(s):

Malcolm Bates; David Mardle; Tim Worden

Other key lawyers:

Elizabeth Rhodes


‘The team provides timely, pragmatic and and commercial advice on our licensing activities which we find very valuable. They are accessible, responsive and keen to understand our aims during transactions and regularly help us navigate complex scenarios given their knowledge and expertise in the market.’

‘Tim Worden provides us with expert coverage as our key contact as well as high quality, deal-specific advice on our licensing activities. He has pulled in trans-Atlantic resources on deals when we have needed it seamlessly and delivers a really high-quality service.’

‘We work especially with Malcolm Bates. Malcolm’s broad and long experience makes interactions and processes run smoothly and efficiently.’

Key clients

Biocon Biologics

Syndesi Therapeutics

Refeyn Limited

Oxford Science Enterprises PLC

Engitix Therapeutics

Synaffix BV

Stalicla SA

Ten Eleven Ventures III, LP

MiroBio Ltd

SV Health Investors

CMR Surgical

Ochre Bio, Inc


Work highlights

  • Advised Biocon Biologics Ltd on its multi-billion-dollar acquisition of the global biosimilars business of its partner Viatris Inc.
  • Advised Synaffix B.V on three license agreements: with Genmab A/S; with Amgen Inc; with Hummingbird Bioscience.
  • Advised Stalicla SA on an in-licensing agreement with Novartis.

Mills & Reeve LLP

In Cambridge, Mills & Reeve LLP houses a multi-disciplinary life sciences practice that advises on transactional issues, patents and IP, and privacy. The 'excellent' James Fry leads the team, and acted for GSK on the spin-off of its consumer health business Haleon plc, having a great deal of expertise in IP licensing and distribution. Fry also notably acts for F-star Therapeutics and NRG Therapeutics. Funds specialist Dona Ardeman, corporate partner Jonathan Greenwood , employment adviser Melanie James and corporate finance expert Zickie Lim are among the key contacts for biotechnology clients.

Practice head(s):

James Fry

Other key lawyers:

Dona Ardeman; Jonathan Greenwood; Melanie James; Zickie Lim


‘Very commercially minded, easy to work with, very flexible and capable.’

‘James Fry is an excellent lawyer.’

Key clients



F-star Therapeutics

Calypso Biotech


NRG Therapeutics

Neurocrine Biosciences

Kadans Science Partners

Kadans Science Partners

Work highlights

  • Advised GSK on the divestment of Haleon plc. The firm assisted with the cloning and renegotiation of hundreds of commercial contracts, ensuring that the new business has continuing supplier arrangements to support it from day 1 of its operation.
  • Advised F-star on its licence and collaboration agreement with Takeda. The agreement which grants licences to Takeda of F-star’s proprietary platform IP relating to the generation of bi-specific antibodies will facilitate research towards the development of a next generation immuno-oncology bispecific antibody.
  • Acted for NRG Therapeutics on its Series A fundraising led by Omega Funds and also including Brandon Capital.

Penningtons Manches Cooper LLP

The Cambridge office of Penningtons Manches Cooper LLP plays a key role in the firm’s life sciences practice, acting for many of the companies based in the local science and technology hub. IP, IT and commercial partner Rachel Bradley, who co-leads the multi-disciplinary group, acted as co-ordinator of the review of all European clinical trial agreements for various different research studies for Applied Molecular Transport, Inc. to govern the clinical trials it is sponsoring across Europe. Employment partner Hilary Aldred and real estate specialist Sarah Coates are key members of the practice.

Practice head(s):

Rachel Bradley

Other key lawyers:

Hilary Aldred; Sarah Coates

Key clients

The Company of Biologists Limited

Applied Molecular Transport, Inc

Fluid Pharma Ltd

Royal National Orthopaedic Hospital

Enterprise Therapeutics

Metrion Biosciences

Abcam PLC

King’s College London

Synox Therapeutics

MitoRx Therapeutics Limited

42 Technology Limited

Oxford Cannabinoid Technologies

Certis Europe B.V.

Birch Tree IP

HutanBio Limited

Flatiron Health, Inc.

Genestack Limited

Work highlights

  • Acting for Applied Molecular Transport, Inc in the review of all European clinical trial agreements. The firm instructed expert local counsel, for multiple clinical studies across Europe, interpreting the advice and seeking instructions from the client’s legal counsel. This project has been on-going for almost 3 years.
  • Advised Fluid Pharma Limited on a co-operation agreement with a contract manufacturer of GMP materials for the development Fluid Pharma’s MicroCoat™ technology. Assisted Fluid Pharma with the drafting and negotiation of the agreement.
  • Advised Flatiron Health, Inc. on the impact of UK data protection, and EU GDPR requirements on Flatiron’s health-tech products.